Etoposide-based therapy for severe forms of COVID-19
Documentos PDF
Imagenes y Videos
Abstract
The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally
due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment.
Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the
standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV
and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to
consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19.
Palabras clave
COVID-19; Haemophagocytic lymphohistiocytosis; HLH; EtoposideLink to resource
https://doi.org/10.1016/j.mehy.2020.109826Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.